Physician profile
Eric Baum
NPI 1285669077
$896,039.66
in general payments reported to CMS, 2019-2025
31 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176K · 2020: $92K · 2021: $111K · 2022: $119K · 2023: $71K · 2024: $213K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $342K · Travel and Lodging: $42K · Food and Beverage: $8,820 · Consulting Fee: $5,650 · Education: $16.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $342,266.75 |
| Travel and Lodging | $41,508.56 |
| Food and Beverage | $8,819.86 |
| Consulting Fee | $5,650.00 |
| Education | $16.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $229,254.22 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $164,413.02 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $124,307.61 | 2019-2025 | |
| Abbvie INC. | $89,331.42 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $84,014.66 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $81,274.10 | 2019-2025 | Dupixent |
| Celgene Corporation | $70,115.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16,063.17 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $10,156.46 | 2019-2022 | |
| Almirall LLC | $8,091.01 | 2019 | |
| Epi Health, LLC | $7,645.45 | 2019-2021 | |
| Pfizer INC. | $6,332.69 | 2019-2022 | |
| Galderma Laboratories, L.P. | $3,276.77 | 2019-2025 | Aklief, Nemluvio |
| Janssen Biotech, INC. | $430.88 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $329.23 | 2019-2025 | Taltz, Ebglyss |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $234.02 | 2019-2021 | |
| Leo Pharma INC. | $219.55 | 2019-2023 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $111.80 | 2021-2025 | Sotyktu |
| Astrazeneca Pharmaceuticals Lp | $68.52 | 2019 | |
| Prugen, INC. Pharmaceuticals | $66.27 | 2019 | |
| Dermavant Sciences, INC. | $59.16 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $48.89 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $42.02 | 2023-2025 | Zoryve |
| Incyte Corporation | $34.64 | 2021 | |
| Aclaris Therapeutics, INC. | $24.65 | 2019 | |
| Dermira, INC. | $18.18 | 2019 | |
| Merz North America, INC. | $17.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.88 | 2023 | Spevigo |
| Taro Pharmaceuticals USA, INC. | $14.24 | 2019 | |
| Organon LLC | $14.09 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.